Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pak J Pharm Sci ; 36(5): 1543-1552, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37869930

RESUMEN

Nanoparticles based TDDS was employed to overcome the adverse effects of oral contraceptives. A transdermal patch of Ethinyl Estradiol (EE) nanoparticles was aimed to provide sustained release of the drug and lower dosage frequency. The patch was designed with Eudragit-based polymeric films or EE-loaded chitosan nanoparticles poured onto a polyvinyl alcohol backing membrane, with a non-ionic surfactant (span-20) and a plasticizer (n-butyl phthalate) using solvent evaporation method. Nanoparticles were analyzed for their size, morphology, yield and entrapment efficiency. The patches were analyzed for their folding endurance, thickness, weight, drug content, in vitro release pattern, FTIR and DSC. All patches were transparent, having a uniform, smooth surface. The folding endurance of all the patches indicated optimum flexibility. In vitro, release and Ex-Vivo permeation studies showed that F1 containing nanoparticles exhibited the most optimum drug release in 72h (97.6%). The release pattern demonstrated was diffusion controlled. FTIR, DSC studies indicated no interaction between drug and excipients. The accelerated stability studies were performed at 40ᵒC and 70% relative humidity for six months. The product was found stable. The developed patches of EE nanoparticles were expected to improve patient compliance by reducing dose frequency and provide optimum therapy by sustained drug release for contraception.


Asunto(s)
Nanopartículas , Absorción Cutánea , Humanos , Etinilestradiol , Sistema de Administración de Fármacos con Nanopartículas , Administración Cutánea , Anticoncepción , Menopausia , Parche Transdérmico , Sistemas de Liberación de Medicamentos/métodos
2.
Cell Mol Biol (Noisy-le-grand) ; 67(5): 27-37, 2022 Feb 04.
Artículo en Inglés | MEDLINE | ID: mdl-35818275

RESUMEN

Fenbfen is used for pain, pyrexia and in the management of osteoarthritis, rheumatoid arthritis and other musculoskeletal disorders. The present research was planned to examine the immunomodulatory activity of fenbufen in different models of cell-mediated immunity (CMI) and humoral immunity (HI). The CMI was evaluated by delayed-type hypersensitivity (DTH) and cyclophosphamide-induced neutropenia assays while HI was appraised by hemagglutination (HA) assay by administering fenbufen at 2, 6 and 10 mg.kg-1 and azathioprine 40 mg.kg-1 (as standard therapy) to albino mice by intraperitoneal route. The ex vivo immunomodulatory action was determined by red blood cell (RBC) membrane stabilization and protein denaturation assays. The results showed that fenbufen treatment had significantly (p<0.05-p<0.001) reduced white blood cells, hemoglobin content, and red blood cells in the healthy and neutropenic mice. A significant (p<0.001) reduction in activities of superoxide dismutase and catalase and glutathione contents, and enhancement of malondialdehyde level were observed in neutropenic mice that were restored by fenbufen treatment. It suppressed DTH reaction after 24, 48 and 72 h post topical application of 2, 4-dinitrofluorobenzene (DNFB). Fenbufen or azathioprine treated groups also showed a significant reduction in the antibody titer against human RBCs induced immune activation in mice as compared to the disease control mice. Fenbufen showed IC50 of 14.0, 50.5 and 66.2 µg.ml-1 whereas, diclofenac sodium showed IC50 of 61.0, 126 and 50.5 µg/ml in RBCs membrane stabilization, egg albumin and bovine serum albumin denaturation assays respectively. The current study shows that fenbufen might have potential immunomodulatory activity against CMI and HI. It can be utilized to treat immune system disorders.


Asunto(s)
Hipersensibilidad Tardía , Animales , Azatioprina/efectos adversos , Humanos , Hipersensibilidad Tardía/inducido químicamente , Hipersensibilidad Tardía/tratamiento farmacológico , Inmunidad Celular , Inmunidad Humoral , Ratones , Fenilbutiratos
3.
Cell Mol Biol (Noisy-le-grand) ; 67(5): 6-15, 2022 Feb 04.
Artículo en Inglés | MEDLINE | ID: mdl-35818277

RESUMEN

The current work was performed to explore the pharmacological mechanisms involved in the management of asthma and hypertension along with the safety profile of the Ceratonia siliqua (C. siliqua/Carob) pods. The bronchorelaxant, vasorelaxant, and cardioselective activities of C. siliqua pods were investigated using isolated rabbit tracheal, aortic, and paired atrial fragments on the Power lab data acquisition system. Normotensive rats were used to study antihypertensive activity. The plant extract and its fractions relaxed the carbachol-induced contraction in the tracheal fragments and shifted the concentration-response curve of carbachol towards the right confirming the muscarinic receptor antagonist activity. The relaxation of phenylephrine-induced contraction in an aortic fragment by the extract showed α- adrenergic blocking activity. Furthermore, the extract produced a cardio-selective response in the paired atria and decreased the blood pressure in anesthetized normotensive rats. The plant extract proved to be non-toxic in oral acute and chronic toxicity studies and did not demonstrate any sign of histopathological lesions. These results suggested that the plant extract was non-toxic and could be used in the management of lifetime therapies of respiratory and cardiovascular disorders without any unwanted effects.


Asunto(s)
Asma , Fabaceae , Hipertensión , Extractos Vegetales , Animales , Asma/tratamiento farmacológico , Carbacol , Fabaceae/química , Hipertensión/tratamiento farmacológico , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Conejos , Ratas
4.
Artículo en Inglés | MEDLINE | ID: mdl-35579124

RESUMEN

BACKGROUND: The plant Berberis aristata is traditionally used and scientifically validated for treating obesity and hyperlipidemia. It is also traditionally used to treat gynecological abnormalities. Therefore, the present study was designed to evaluate the therapeutic potential of Berberis aristata for obesity-related reproductive changes and chemically characterize it. METHODS: High-fat diet was given to 36 female rats for six weeks to induce obesity and infertility. These obese rats were treated with 10 mg/kg orlistat or the plant extract at 125-500 mg/kg for 45 days. RESULTS: The GC-MS analysis of the plant extract included fructose, thymic acid and other hydrocarbons. The plant extract revealed a remarkable free radical scavenging activity. The treated animals exhibited a decrease in total cholesterol and triglycerides (p<0.001), insulin and leptin levels (p<0.05), visceral fat, and body weight while increasing the estradiol level at 500 mg/kg dose of the plant extract as compared with untreated animals as demonstrated from the histology of the ovary. Oxidative stress biomarkers such as superoxide dismutase, nitric oxide, malondialdehyde and reduced glutathione were significantly (p<0.01-0.001) ameliorated in treated rats. CONCLUSION: B. aristata exhibited substantial potential against obesity-inducedreproductive damage in female rats by reducing oxidative stress and resistance to leptin and insulin.


Asunto(s)
Berberis , Resistencia a la Insulina , Femenino , Ratas , Animales , Insulina/metabolismo , Ratas Wistar , Leptina , Dieta Alta en Grasa , Berberis/química , Berberis/metabolismo , Extractos Vegetales/farmacología , Obesidad/tratamiento farmacológico , Estrés Oxidativo
5.
Artículo en Inglés | MEDLINE | ID: mdl-33563161

RESUMEN

BACKGROUND & OBJECTIVE: Peganum harmala has been traditionally used to manage rheumatoid arthritis (RA) and other inflammatory conditions. However, its use against RA has not been scientifically evaluated. The current study was designed to assess the anti-arthritic and anti-inflammatory activities of the methanolic extract of P. harmala leaves by in vitro and in vivo methods. METHODS: The in vitro assays were carried out to determine the effect of plant extract on inhibition of egg albumin denaturation and human red blood cell membrane (HRBC) stabilization. Moreover, 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity was performed to determine the antioxidant potential. In vivo anti-arthritic activity was performed by determining the curative effect against Complete Freund's adjuvant (0.1 ml). The plant extract was administered to rats orally at 200, 400 and 600 mg/kg/day for 21 days. RESULTS: The values of IC50 of plant extract in protein denaturation, stabilization of HRBC and DPPH assays were 77.54 mg/ml, 23.90 mg/ml and 58.09 µg/ml, respectively. Moreover, the plant extract significantly attenuated the poly-arthritis and weight loss, anemia and paw edema. The plant extract restored the level of C-reactive protein, rheumatoid factor, alanine transaminase, aspartate transaminase and alkaline phosphatase in poly-arthritic rats. Moreover, the plant extract restored the immune organs' weight in treated rats. Treatment with P. harmala also significantly subdued the oxidative stress by reinstating superoxide dismutase, reduced glutathione, catalase and malondialdehyde in poly-arthritic rats. The plant extract notably restored the prostaglandin-E2 and tumor necrosis factor (TNF)-α in the serum of poly-arthritic rats. CONCLUSION: It was concluded that P. harmala extract had potential antioxidant, anti-inflammatory and antiarthritic activities, which primarily might be attributed to alkaloids, flavonoids and phenols.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Peganum/química , Extractos Vegetales/uso terapéutico , Animales , Antiinflamatorios/uso terapéutico , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Artritis Experimental/patología , Células Cultivadas , Membrana Eritrocítica/efectos de los fármacos , Membrana Eritrocítica/metabolismo , Adyuvante de Freund/farmacología , Adyuvante de Freund/uso terapéutico , Humanos , Medicina Tradicional , Fitoterapia , Plantas Medicinales/química , Ratas
6.
Des Monomers Polym ; 24(1): 240-258, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34434070

RESUMEN

In the current research, attempt is made to fabricate a nanoemulsion (NE) containing an antifungal agent. The prepared formulation has been expected to enhance skin penetration. It is also studied for in vitro drug release and toxicity assessment. Spontaneous titration method was used for preparation of NE. Prepared NE were characterized for their charge, size, morphology, rheological behaviour, drug release profile, skin permeability. The drug permeation and skin irritation were investigated. The in vitro antifungal activity was inspected using the well agar diffusion method. Miconazole NE showed good penetration in the skin as compared to marketed products. SEM showed semispherical shapes of the droplets. Zeta potential and zeta sizer showed that size was in nano ranges having positive charge.

7.
Pak J Pharm Sci ; 34(6(Supplementary)): 2371-2377, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35039276

RESUMEN

To evaluate the anti-diabetic potential of aqueous methanolic extract of Conyza bonariensis amongst the Wistar rats. Phytochemical and High Performance Liquid Chromatography (HPLC) analyses of phenols and flavonoids were examined. The plant extract (250 and 500mg/kg/day) was explored for its anti-hyperglycemic effect for 14 days in normoglycemic and alloxan-induced diabetic rats using the oral glucose tolerance test (OGTT). HPLC analyses demonstrated the composition of the plant extract as gallic acid, cinnamic acid, quercetin, p-coumaric acid and syringic acid. The blood glucose concentrations in experimental diabetic as well as non-diabetic rats significantly decreased with doses 250 and 500 mg/kg in OGTT. Moreover, the significant drop in fasting glucose level was observed following 14 days of therapy. It also ameliorated the serum cholesterol, total protein, low and high density lipoproteins, glycosylated hemoglobin A1C and serum amylase with respect to untreated rats suffering from diabetes. There appeared to be no significant alteration with regard to body weight amongst the treated rats. The plant extract revamped the pancreatic islets of Langerhans and abridged alloxan-induced degenerative changes in the liver. It can be concluded that Conyza bonariensis extract has a pronounced hypoglycemic effect on diabetes due to the presence of phytochemicals.


Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/farmacología , Fitoquímicos/farmacología , Extractos Vegetales/farmacología , Aloxano , Animales , Biomarcadores/sangre , Glucemia/metabolismo , Conyza/química , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/patología , Femenino , Hemoglobina Glucada/metabolismo , Hipoglucemiantes/aislamiento & purificación , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Fitoquímicos/aislamiento & purificación , Extractos Vegetales/aislamiento & purificación , Ratas Wistar
8.
Pak J Pharm Sci ; 33(1(Supplementary)): 343-353, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32122867

RESUMEN

Fast dissolving orodispersible film (ODF) was prepared for concurrent administration of biopharmaceutical classification system (BCS) class II drugs, i.e., meloxicam (MX) and tizanidine (TZ), using natural (xanthan gum), semisynthetic (hydroxypropyl methylcellulose and hydroxyethyl cellulose) and synthetic (polyvinyl alcohol) polymers. Compatibility of the ingredients of ODFs was ascertained through Fourier transform infra-red spectroscopy and differential scanning calorimetry. ODFs were characterized through disintegration time, pH of the surface of film, tensile strength, folding endurance, % elongation and content uniformity (MX and TZ) which were found in the range between 17±1.3-56±3.1 s, 5.11±0.07-6.28±0.05, 14.721±1.2-33.084±3.1 N/m2, > 100, 3.33±0.53-10.04±0.77 % and 98.01-99.34 % (MX) and 97.48-99.03 % (TZ), respectively. The values of moisture uptake, moisture loss and loss on drying of all formulations were in the range from 1.06±0.09-7.51±0.93 %, 0.06±0.01-2.3±0.08 % and 0.008±0.002-0.03±0.03 %, respectively. In vitro drug release study in simulated saliva fluid of pH 7.4 has shown that > 90 % MX and TZ was released within 5 min. Visual inspection, scanning electron microscope and X-ray diffraction analysis of all ODFs expressed their smooth surfaces. ODF prepared from xanthan gum (F5) exhibited better physicochemical and mechanical properties as compared to other formulations.


Asunto(s)
Productos Biológicos/química , Clonidina/análogos & derivados , Composición de Medicamentos/métodos , Diseño de Fármacos , Meloxicam/química , Administración Oral , Productos Biológicos/administración & dosificación , Productos Biológicos/farmacocinética , Clonidina/administración & dosificación , Clonidina/química , Clonidina/farmacocinética , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Liberación de Fármacos , Meloxicam/administración & dosificación , Meloxicam/farmacocinética , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier/métodos
9.
Pak J Pharm Sci ; 32(3 (Supplementary)): 1167-1173, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-31303586

RESUMEN

Medicinal plants are playing an imperative role in the therapy for treating various chronic ailments including arthritis. The present study was focused on finding in-vitro and in-vivo anti-arthritic potential of P. braunii roots. In vitro protein denaturation, membrane stabilization and anti-trypsinase assays were carried out to demonstrate anti-arthritic activity of the extracts. Furthermore, the extracts exerting promising in vitro anti-arthritic potential were tested orally at 150, 300 and 600mg/kg/day against formaldehyde induced arthritis in Wistar rats. The methanolic, aqueous and ethyl acetate extracts of the plant revealed noteworthy in vitro anti-arthritic activities while mitigating formaldehyde induced paw edema in dose dependent manner. Methanolic and aqueous extracts showed the highest inhibition (p<0.05) of paw edema, arthritic indices, reduced elevated level of platelets and leukocytes while increasing hemoglobin and body weight of arthritic rats. Anti-arthritic activity of the plant extracts may be due to inhibition of protein denaturation and lysosomal membrane stabilization. The plant exhibited good anti-arthritic potential.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Extractos Vegetales/farmacología , Plantas Medicinales/química , Polystichum/química , Albúminas/química , Albúminas/efectos de los fármacos , Animales , Artritis Experimental/inducido químicamente , Evaluación Preclínica de Medicamentos , Membrana Eritrocítica/efectos de los fármacos , Femenino , Formaldehído/toxicidad , Humanos , Masculino , Medicina Tradicional de Asia Oriental , Pakistán , Extractos Vegetales/química , Raíces de Plantas/química , Desnaturalización Proteica/efectos de los fármacos , Ratas Wistar , Albúmina Sérica Bovina/efectos de los fármacos
10.
Pak J Pharm Sci ; 32(1(Supplementary)): 333-338, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30829212

RESUMEN

A simple, rapid and accurate reverse phase high performance liquid chromatographic (RP- HPLC) method was developed for the quantification of lornoxicam in oral disintegrating tablets (ODTs) and in rabbit's plasma. C18 Hypersil™ column was used as stationary phase to separate the drug. Mobile phase methanol: acetonitrile: water (60:30:10) was run isocratically at flow rate of 1 mL/min at room temperature. Mean retention time was 4.23 minutes and minimum amount of lornoxicam that can be measured was 7 ng/mL in rabbit's plasma. Good linearity was observed in concentration range of 10-100 ng/mL with regression coefficient R2 value of 0.9989 and slope value 23773. As per ICH norms, developed method was validated in terms of interday, intraday precision, accuracy, specificity, limit of detection (LOD), limit of quantification (LOQ) and drug plasma stability studies. All the data obtained revealed that this method can be used for in-vitro and in-vivo determination of lornoxicam in various pharmaceutical preparations.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Cromatografía de Fase Inversa/métodos , Piroxicam/análogos & derivados , Administración Oral , Animales , Calibración , Estabilidad de Medicamentos , Límite de Detección , Piroxicam/administración & dosificación , Piroxicam/sangre , Conejos , Sensibilidad y Especificidad , Comprimidos/administración & dosificación
11.
Acta Pol Pharm ; 71(3): 415-21, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25265821

RESUMEN

Current study was conducted to investigate antimicrobial activity of fruit extracts of two Solanaceous plants (Solanum nigrum and Solanum xanthocarpum) found in Pakistan. Petroleum ether, chloroform, dichloromethane, ethyl acetate, acetone, methanol and water were utilized for extraction. The highest percentages of polar components of both the species were extracted by water; little amount of non-polar components by petroleum ether while very low quantities by other solvents. Antimicrobial activities were estimated by measuring zones of inhibition through hole-plate diffusion method, against three species of Gram positive bacteria, five species of Gram negative bacteria and three species of fungi selected for this study. Doses of 5, 10 and 15 mg/mL prepared through methanolic extracts of each plant's powdered fruit material displayed significant zones of inhibition against all three Gram positive bacteria, three of the Gram negative bacteria out of five and against all three fungi. Although these doses exhibited significant zones of inhibition but they are not as potent as standards: ampicillin or amphotericin B. The present study assures the possible potential of antimicrobial as well as antifungal activity of fruit extracts of these plants.


Asunto(s)
Antibacterianos/farmacología , Antifúngicos/farmacología , Extractos Vegetales/farmacología , Solanum nigrum , Pruebas Antimicrobianas de Difusión por Disco , Relación Dosis-Respuesta a Droga , Frutas , Hongos/efectos de los fármacos , Hongos/crecimiento & desarrollo , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Gramnegativas/crecimiento & desarrollo , Bacterias Grampositivas/efectos de los fármacos , Bacterias Grampositivas/crecimiento & desarrollo , Metanol/química , Fitoterapia , Plantas Medicinales , Solventes/química
12.
Acta Pol Pharm ; 71(2): 287-95, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25272649

RESUMEN

This study was aimed to determine effects of penetration enhancers and plasticizers on drug release from rationally designed formulations of flurbiprofen based transdermal drug delivery system. Matrix type transdermal patches were formulated with ethyl cellulose (EC) as a polymer by using plate casting method. The plasticizers such as propylene glycol (PG) and dibutyl phthalate (DBP), and enhancers such as Span 20, Tween 20, sodium lauryl sulfate (SLS), isopropyl myristate (IPM) and ethanol (EtOH) were formulated in different concentrations in the patches. Such different combinations of polymer with various enhancers and plasticizers in patches were evaluated for their effect on the physicochemical properties and drug release behavior of flurbiprofen. The drug release study was carried out by the paddle-over-disk method and permeation of drug was performed by Franz diffusion cell using rabbit skin. Patches having ethanol with ethyl cellulose showed more uniformity in the physical properties while the smoothness and clarity of patches containing sodium lauryl sulfate were not satisfactory. The drug release from patches followed Higuchi and Korsmeyer-Pappas model while maximum drug release was obtained by isopropyl myristate (903 microg). It was concluded that the patches having ethyl cellulose with isopropyl myristate and propylene glycol are more useful for transdermal patches of flurbiprofen.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Celulosa/análogos & derivados , Excipientes/química , Flurbiprofeno/farmacocinética , Administración Cutánea , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Celulosa/química , Difusión , Composición de Medicamentos/métodos , Flurbiprofeno/administración & dosificación , Miristatos/química , Plastificantes/química , Propilenglicol/química , Conejos , Absorción Cutánea , Parche Transdérmico
13.
Acta Pol Pharm ; 70(4): 749-57, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23923399

RESUMEN

Gliclazide is an oral hypoglycemic agent, indicated in non insulin dependent diabetes mellitus and in patients with diabetic retinopathy. It has good tolerability and is a short acting sulfonyl urea that requires large dose to maintain the blood glucose level. So development of a sustained release formulation of gliclazide (GLZ) is required for better patient compliance. This study was conducted to assess the effects of different drug polymer ratios on the release profile of gliclazide from the matrix. Oral matrix tablets of gliclazide were prepared by hot melt method, using pure and blended mixture of glyceryl monostearate (GMS) and stearic acid (SA) in different ratios. In vitro release pattern was studied for 8 h in phosphate buffer media (pH 7.4). Different kinetic models including zero order, first order, Higuchi and Peppas were applied to evaluate drug release behavior. Drug excipient compatibility was evaluated by scanning with DSC and FTIR. Higuchi model was found the most appropriate model for describing the release profile of GLZ and non-Fickian release was found predominant mechanism of drug release. The release of drug from the matrix was greatly controlled by GMS while SA appeared to facilitate the release of drug from matrix tablets. FTIR results showed no chemical interaction between drug and the polymers, and DSC results indicated amorphous state of GLZ and polymers without significant complex formation. The results indicate that matrix tablets of gliclazide using glyceryl monostearate and stearic acid showed marked sustained release properties.


Asunto(s)
Excipientes/química , Gliclazida/química , Glicéridos/química , Hipoglucemiantes/química , Ácidos Esteáricos/química , Administración Oral , Tampones (Química) , Rastreo Diferencial de Calorimetría , Química Farmacéutica , Preparaciones de Acción Retardada , Estabilidad de Medicamentos , Gliclazida/administración & dosificación , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Hipoglucemiantes/administración & dosificación , Cinética , Modelos Químicos , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Comprimidos , Tecnología Farmacéutica/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...